Premium
Prasugrel (Efient): new antiplatelet to prevent atherothrombosis
Author(s) -
Chaplin Steve,
Nadra Imad,
Redwood Simon
Publication year - 2010
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.611
Subject(s) - prasugrel , medicine , acute coronary syndrome , percutaneous coronary intervention , clopidogrel , cardiology , adverse effect , myocardial infarction
Prasugrel (Efient) is a new antiplatelet agent to prevent atherothrombotic events in patients with acute coronary syndrome or STEMI under‐ going percutaneous coronary intervention. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Drs Nadra and Redwood consider its potential place in treatment. Copyright © 2010 Wiley Interface Ltd